Abstract:Abstract 2528 Background: Minimal residual disease(MRD) is currently the most powerful prognostic indicator in childhood ALL as well as in adult ALL. Using neonatal NOD/SCID/IL2rγnull xenotransplantation model, we previously demonstrated that CD34+CD38+CD19+ cells as well as CD34+CD38−CD19+ cells have the capacities to initiate B-ALL in vivo and to self-renew, that is, CD34+CD19+ cells are leukemia initiating cells(LICs) in human B-precursor ALL (B-ALL)(Kong Y et al. Leukemia 2008; 22: 1207–1213). Nevertheless, immunophenotypic differences between B-ALL initiating cells and normal progenitor B cells have not been clearly clarified. Especially, whether the LICs identified in xenotransplantation assay are clinically useful for routine MRD monitoring in B-ALL patients is largely unknown. Objective: To compare phenotypic characteristics of LICs in B-ALL patients to that of normal progenitor B cells in healthy donors. To evaluate clinical significances of LICs as novel MRD markers in predicting relapses in human B-precursor ALL. Materials and methods: To identify new markers for MRD detection in B-ALL, we compared phenotypic characterization of LICs from 40 patients with newly diagnosed B-ALL and 40 patients with relapsed B-ALL to that of normal progenitor B cells from 40 healthy donors by seven-color flow cytometry (FCM). Comparative analysis was performed at mean fluorescence intensity (MFI) of CD38, CD45, CD58 and CD123 on CD34+CD19+ cells among the above three groups. Subsequently, the most promising markers were examined in detail for their usefulness as MRD markers by seven-color FCM at different time points in 823 patients (including pediatric and adult patients) with B-ALL from January 2010 to June 2011 at Peking University Institute of Hematology. A total of 1,050,000 events were routinely collected. More than 0.001% of LICs with aberrant highly expression of CD123 and/or CD58 in bone marrow samples detected by seven-color FCM were defined as FCM positive (FCM+). FCM positivity at any time was defined as MRD positive (FCM MRD+), all others cases were defined as MRD negative (FCM MRD−). Real-time quantitative polymerase chain reaction (RQ-PCR) was applied concurrently to evaluate MRD in Philadelphia chromosome positive ALL (Ph+ ALL) patients. The value of BCR/ABL equal to 0 was defined as RQ-PCR negative (RQ-PCR-). The results of MRD studies by the two methods were recorded independently. Results: MFI of CD58(3.46±1.85 vs.3.82±1.83 vs.1.35±0.77, p <0.001) and CD123(6.37±3.47 vs.7.56±3.90 vs. 3.66±1.94, p <0.001) was significantly higher on LICs from newly diagnosed B-ALL and relapsed B-ALL than that of their normal counterparts. Meanwhile, MFI of CD38(8.09±6.36 vs.11.23±8.59 vs. 37.89±7.91, p <0.05) and CD45(7.42±5.14 vs.9.91±7.72 vs.13.50±8.20, p <0.05) was significantly lower on LICs than that of their normal counterparts. Further ANOVA analysis by LSD method demonstrated MFI of CD38, CD45, CD58 and CD123 on LICs differed significantly from that of normal progenitor B cells, whereas the phenotypic differences on LICs from newly diagnosed B-ALL or relapsed B-ALL showed no statistically significance. In the sequential MRD follow up, 185 samples from110 cases of B-ALL were detected as FCM MRD+. Among them, LICs from 56 cases(51%) with aberrant highly CD58 expression, 106 cases(96%) with aberrant highly CD123 expression and 40 cases(36%) with simultaneously aberrant highly expressions of CD58 and CD123. Twenty-two cases relapsed during MRD monitoring, of them 19 cases were detected as FCM MRD+ at a median time of 57 days (13–90days) before their recurrence. The left 3 relapsed cases did not monitor MRD status for about 3 months as we expected. MRD analysis was performed concurrently by both RQ-PCR and FCM in 85 follow-up bone marrow samples from 23 Ph+ ALL patients. A good correlation was found between RQ-PCR and FCM (Spearman r=0.883, p < 0.001). Conclusions: Mean fluorescence intensity of CD38, CD45, CD58 and CD123 antigens distinguished B-ALL initiating cells from their normal counterparts, CD34+CD19+ normal progenitor B cells. The B-ALL initiating cells with aberrant highly expression of CD123 and/or CD58 detected by seven-color FCM may serve as promising markers for MRD monitoring in B-ALL. Disclosures: No relevant conflicts of interest to declare.

Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry

Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia

Different Minimal Residual Disease Levels Between Childhood Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Detected with Multi-Parameter Flow Cytometry.

[Detection of Minimal Residual Disease in B Lineage Acute Lymphoblastic Leukemia by 4-Color Flow Cytometry].

[The Clinical Significance of Detecting Minimal Residual Disease in Acute Childhood B-cell Lymphoblastic Leukemia with Flow Cytometry].

The Clinical Significane of Detecting Minimal Residual Disease with Acute Myeloid Leukemia by Flow Cytometry

Predictable Recurrence By Regular Monitoring Minimal Residual Disease With Flowcytometry In The Patients With Both Aml And All: A Single-Center Study Of 158 Cases

Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia by Multi-Parameter Flow Cytometry

Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia

Leukemia Initiating Cells: New Markers for Minimal Residual Disease Monitoring in B-Precursor Acute Lymphoblastic Leukemia

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

Clinical value of flow cytometry in monitoring minimal residual disease of children with acute B-lymphocytic leukemia

Microfluidic Affinity Selection of B-Lineage Cells from Peripheral Blood for Minimal Residual Disease Monitoring in Pediatric B-Type Acute Lymphoblastic Leukemia Patients

THE SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC LEUKAEMIA: A SINGLE CENTRE STUDY

Measurable Residual Disease Analysis by Flow Cytometry and Correlation With Molecular Measurable Residual Disease in Acute Promyelocytic Leukemia: A Real-World Prospective Study

Detection of the Minimal Residual Disease of 53 Cases with Acute Myelocyte Leukemia by Flow Cytometry

[Prognostic Significance of Minimal Residual Disease Detected by Multiparameter Flow Cytometry in Acute Myeloid Leukemia].

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia

Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.